Bi-ventricular assist
This article was originally published in The Gray Sheet
Executive Summary
Biophan Technologies will direct the development, regulatory approval and marketing of Myotech's Myo-Vad minimally invasive bi-ventricular assist device. Myo-Vad is based on Myotech's Direct Mechanical Ventricular Assist (DMVA) technology - a flexible polymer cup installed around the heart through a small incision in about three minutes. The cup, featuring a pneumatically activated liner connected to a control line, compresses and expands to support both ventricles of the heart. The technology has been tested in over 700 animals...
You may also be interested in...
Biophan, Siemens sign pact
Development and commercialization of magnetic resonance imaging technologies is the goal of a new research collaboration inked between Biophan Europe and Siemens' MRI division. The deal follows Biophan's successful development of an MRI system to visualize implanted medical devices, such as heart valves, and Siemens' unveiling of a new MRI scanning technology, the 1.5 T wide-aperture Magnetrom Espree (1"The Gray Sheet" Sept. 19, 2005, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.